Ensifentrine/glycopyrrolate - Verona Pharma
Alternative Names: Glycopyrrolate/ensifentrine - Verona PharmaLatest Information Update: 14 Aug 2024
At a glance
- Originator Verona Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifibrotics; Antispasmodics; Antiulcers; Bronchodilators; Imines; Isoquinolines; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules; Urea compounds
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Muscarinic receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 08 Aug 2024 Verona Pharma plans a phase II trial for Chronic obstructive pulmonary disease in third quarter of 2024
- 31 Jul 2024 Verona Pharma files an IND application with the US FDA in for Chronic obstructive pulmonary disease before July 2024
- 09 Nov 2023 Verona Pharma plans to submit IND application to the US FDA for Chronic obstructive pulmonary disease in second half of 2024